The emerging role of RNA N6-methyladenosine methylation in breast cancer

被引：0
|
作者：
Fangchao Zheng
Feng Du
Jiuda Zhao
Xue Wang
Yiran Si
Peng Jin
Haili Qian
Binghe Xu
Peng Yuan
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital
[2] Peking University Cancer Hospital and Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department
[3] Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University,Breast Disease Diagnosis and Treatment Center
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of VIP Medical Services, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital
[5] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Surgery, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital
[6] Chinese Academy of Medical Sciences and Peking Union Medical College,State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute
来源：
Biomarker Research | / 9卷
关键词：
RNA methylation; Breast cancer; Clinicopathological features; Prognosis; Drug target;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
N6-methyladenosine (m6A) modification is the most prevalent internal mRNA modification and is involved in many biological processes in eukaryotes. Accumulating evidence has demonstrated that m6A may play either a promoting or suppressing role in breast cancer, including in tumorigenesis, metastasis and angiogenesis. In this review, we summarize the latest research progress on the biological function and prognostic value of m6A modification in breast cancer, as well as potential related therapeutic strategies.
引用
收藏
相关论文
共 50 条
  • [1] The emerging role of RNA N6-methyladenosine methylation in breast cancer
    Zheng, Fangchao
    Du, Feng
    Zhao, Jiuda
    Wang, Xue
    Si, Yiran
    Jin, Peng
    Qian, Haili
    Xu, Binghe
    Yuan, Peng
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [2] Emerging role of N6-methyladenosine RNA methylation in lung diseases
    Xu, Limin
    Zhou, Lingyan
    Yan, Chenxin
    Li, Liqin
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (20) : 1862 - 1872
  • [3] The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance
    Chen, Zhaolin
    Hu, Ying
    Jin, Le
    Yang, Fan
    Ding, Haiwen
    Zhang, Lei
    Li, Lili
    Pan, Tingting
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer
    Hu, Xiaoge
    Lei, Xiangxiang
    Guo, Jinhui
    Fu, Wen
    Sun, Wen
    Lu, Qiliang
    Su, Wei
    Xu, Qiuran
    Tu, Kangsheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Role of identified RNA N6-methyladenosine methylation in liver
    Xu, Kechen
    Sun, Yuchao
    Sheng, Baixiang
    Zheng, Yiwen
    Wu, Xiaoli
    Xu, Keyang
    ANALYTICAL BIOCHEMISTRY, 2019, 578 : 45 - 50
  • [6] The emerging roles of N6-methyladenosine RNA methylation in human cancers
    Huafei Shen
    Yifen Lan
    Yanchun Zhao
    Yuanfei Shi
    Jie Jin
    Wanzhuo Xie
    Biomarker Research, 8
  • [7] The emerging roles of N6-methyladenosine RNA methylation in human cancers
    Shen, Huafei
    Lan, Yifen
    Zhao, Yanchun
    Shi, Yuanfei
    Jin, Jie
    Xie, Wanzhuo
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [8] Role of N6-methyladenosine RNA modification in cancer
    Qu, Yi
    Gao, Nannan
    Zhang, Shengwei
    Gao, Limin
    He, Bing
    Wang, Chao
    Gong, Chunli
    Shi, Qiuyue
    Li, Zhibin
    Yang, Shiming
    Xiao, Yufeng
    MEDCOMM, 2024, 5 (09):
  • [9] Role of RNA N6-methyladenosine methylation in endothelial response to flow
    Chien, Chian Shiu
    Song, Hui-Yung
    Chiou, Shih-Hwa
    Chien, Shu
    FASEB JOURNAL, 2018, 32 (01):
  • [10] The Role of N6-Methyladenosine Methylation in the Progression of Endometrial Cancer
    Song, Kewei
    Xu, Hongxia
    Wang, Changhe
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (09) : 737 - 749
12345